According to global cancer data, lung cancer was the leading cause of cancer‑related death
in 2020. With the diversification of treatment strategies, the survival outcomes of patients with …

The advent of targeted therapy in non-small-cell lung cancer (NSCLC) has made the routine
molecular diagnosis of EGFR mutations crucial for optimal patient management. Obtaining …

Non–small cell lung cancer (NSCLC) with activating EGFR mutations in exon 19 and 21
typically responds to EGFR tyrosine kinase inhibitors (TKI); however, for some patients …

Aims Lung adenocarcinoma consists of multiple therapeutic targets, however, patients will
inevitably progress to later stage diagnosis with Tyrosine Kinase Inhibitor treatment …

As a Second generation tyrosine kinase inhibitor (TKI), afatinib is approved to treat
advanved/metastatic EGFR-mutant NSCLC (non-small cell lung cancer). However, the …

Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is an
excellent therapeutic agent to treat EGFR mutation-positive non-small cell lung cancer …

Objectives: Lung adenocarcinoma accounts for approximately half of lung cancer cases.
Twenty to 50% of tumors of this type harbor mutations affecting epidermal growth factor …

Background Non-small cell lung cancer (NSCLC) harboring EGFR-sensitizing mutations has
a distinct biology and heterogeneous clinical behavior. We evaluated the characteristics to …

Introduction: Liquid biopsies (LB) are used routinely in clinical practice in two situations for
late stage non-small-cell lung cancer (NSCLC) patients,(i) at the initial diagnosis when …

BACKGROUND Icotinib could have potential effect and tolerability when used sequentially
with chemotherapy for advanced epidermal growth factor receptor (EGFR)-mutated non …